J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Classement en actions
#3896
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Prix de l'action
$26.58
Dernière synchronisation: 2026-07-23
Capitalisation boursière
$4.24B
Changement (1 jour)
0.00%
Changement (1 an)
38.40%
Pays
IN
Échange J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Catégorie
Healthcare
Bénéfices pour J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Bénéfices en Mar 2026 TTM : $105.10M
Selon les derniers rapports financiers de J. B. Chemicals & Pharmaceuticals Limited, les bénéfices actuels de l'entreprise sont de $105.10M. En 2024, l'entreprise a réalisé un bénéfice de $90.13M, une augmentation par rapport à celui de 2023 qui était de $67.56M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour J. B. Chemicals & Pharmaceuticals Limited de 2005 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $105.10M | 1.29% |
| 2025 | $103.76M | 15.12% |
| 2024 | $90.13M | 33.40% |
| 2023 | $67.56M | 1.58% |
| 2022 | $66.51M | -18.43% |
| 2021 | $81.54M | 76.06% |
| 2020 | $46.31M | 12.06% |
| 2019 | $41.33M | 38.74% |
| 2018 | $29.79M | -15.99% |
| 2017 | $35.46M | 12.49% |
| 2016 | $31.52M | 35.13% |
| 2015 | $23.33M | 59.89% |
| 2014 | $14.59M | -23.47% |
| 2013 | $19.06M | -88.54% |
| 2012 | $166.34M | 348.33% |
| 2011 | $37.10M | 12.53% |
| 2010 | $32.97M | 351.68% |
| 2009 | $7.30M | -33.14% |
| 2008 | $10.92M | -33.49% |
| 2007 | $16.41M | -11.60% |
| 2006 | $18.57M | 22.45% |
| 2005 | $15.16M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,578.98% |
IN
|
